117 related articles for article (PubMed ID: 18045204)
1. A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase.
Dhagat U; Carbone V; Chung RP; Matsunaga T; Endo S; Hara A; El-Kabbani O
Med Chem; 2007 Nov; 3(6):546-50. PubMed ID: 18045204
[TBL] [Abstract][Full Text] [Related]
2. Structure-guided design, synthesis, and evaluation of salicylic acid-based inhibitors targeting a selectivity pocket in the active site of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1).
El-Kabbani O; Scammells PJ; Gosling J; Dhagat U; Endo S; Matsunaga T; Soda M; Hara A
J Med Chem; 2009 May; 52(10):3259-64. PubMed ID: 19397269
[TBL] [Abstract][Full Text] [Related]
3. Structure-based optimization and biological evaluation of human 20α-hydroxysteroid dehydrogenase (AKR1C1) salicylic acid-based inhibitors.
El-Kabbani O; Scammells PJ; Day T; Dhagat U; Endo S; Matsunaga T; Soda M; Hara A
Eur J Med Chem; 2010 Nov; 45(11):5309-17. PubMed ID: 20850205
[TBL] [Abstract][Full Text] [Related]
4. Derivatives of pyrimidine, phthalimide and anthranilic acid as inhibitors of human hydroxysteroid dehydrogenase AKR1C1.
Brozic P; Cesar J; Kovac A; Davies M; Johnson AP; Fishwick CW; Lanisnik Rizner T; Gobec S
Chem Biol Interact; 2009 Mar; 178(1-3):158-64. PubMed ID: 19007763
[TBL] [Abstract][Full Text] [Related]
5. Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone.
Higaki Y; Usami N; Shintani S; Ishikura S; El-Kabbani O; Hara A
Chem Biol Interact; 2003 Feb; 143-144():503-13. PubMed ID: 12604236
[TBL] [Abstract][Full Text] [Related]
6. Phytoestrogens as inhibitors of the human progesterone metabolizing enzyme AKR1C1.
Brozic P; Smuc T; Gobec S; Rizner TL
Mol Cell Endocrinol; 2006 Oct; 259(1-2):30-42. PubMed ID: 16962702
[TBL] [Abstract][Full Text] [Related]
7. Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3.
Beranič N; Gobec S; Rižner TL
Chem Biol Interact; 2011 May; 191(1-3):227-33. PubMed ID: 21182831
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of human 20α-hydroxysteroid dehydrogenase (AKR1C1).
El-Kabbani O; Dhagat U; Hara A
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):105-11. PubMed ID: 21050889
[TBL] [Abstract][Full Text] [Related]
9. Probing the inhibitor selectivity pocket of human 20α-hydroxysteroid dehydrogenase (AKR1C1) with X-ray crystallography and site-directed mutagenesis.
El-Kabbani O; Dhagat U; Soda M; Endo S; Matsunaga T; Hara A
Bioorg Med Chem Lett; 2011 Apr; 21(8):2564-7. PubMed ID: 21414777
[TBL] [Abstract][Full Text] [Related]
10. Factorizing the role of a critical leucine residue in the binding of substrate to human 20alpha-hydroxysteroid dehydrogenase (AKR1C1): molecular modeling and kinetic studies of the Leu308Val mutant enzyme.
Dhagat U; Endo S; Soda M; Hara A; El-Kabbani O
Bioorg Med Chem Lett; 2010 Sep; 20(17):5274-6. PubMed ID: 20656485
[TBL] [Abstract][Full Text] [Related]
11. Overview of human 20 alpha-hydroxysteroid dehydrogenase (AKR1C1): Functions, regulation, and structural insights of inhibitors.
Chu X; He S; Liu Y; Liu Y; Feng F; Guo Q; Zhao L; Sun H
Chem Biol Interact; 2022 Jan; 351():109746. PubMed ID: 34780792
[TBL] [Abstract][Full Text] [Related]
12. Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling.
Ji Q; Aoyama C; Nien YD; Liu PI; Chen PK; Chang L; Stanczyk FZ; Stolz A
Cancer Res; 2004 Oct; 64(20):7610-7. PubMed ID: 15492289
[TBL] [Abstract][Full Text] [Related]
13. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones.
Penning TM; Burczynski ME; Jez JM; Hung CF; Lin HK; Ma H; Moore M; Palackal N; Ratnam K
Biochem J; 2000 Oct; 351(Pt 1):67-77. PubMed ID: 10998348
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library.
Brožič P; Turk S; Adeniji AO; Konc J; Janežič D; Penning TM; Lanišnik Rižner T; Gobec S
J Med Chem; 2012 Sep; 55(17):7417-24. PubMed ID: 22881866
[TBL] [Abstract][Full Text] [Related]
15. Characterization of homogeneous recombinant rat ovarian 20alpha-hydroxysteroid dehydrogenase: fluorescent properties and inhibition profile.
Ma H; Penning TM
Biochem J; 1999 Aug; 341 ( Pt 3)(Pt 3):853-9. PubMed ID: 10417353
[TBL] [Abstract][Full Text] [Related]
16. Design and development of novel inhibitors of aldo-ketoreductase 1C1 as potential lead molecules in treatment of breast cancer.
Verma P; Hassan MI; Singh A; Singh IK
Mol Cell Biochem; 2021 Aug; 476(8):2975-2987. PubMed ID: 33770316
[TBL] [Abstract][Full Text] [Related]
17. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer.
Rizner TL; Smuc T; Rupreht R; Sinkovec J; Penning TM
Mol Cell Endocrinol; 2006 Mar; 248(1-2):126-35. PubMed ID: 16338060
[TBL] [Abstract][Full Text] [Related]
18. New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3.
Stefane B; Brozic P; Vehovc M; Rizner TL; Gobec S
Eur J Med Chem; 2009 Jun; 44(6):2563-71. PubMed ID: 19237229
[TBL] [Abstract][Full Text] [Related]
19. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
Penning TM; Burczynski ME; Jez JM; Lin HK; Ma H; Moore M; Ratnam K; Palackal N
Mol Cell Endocrinol; 2001 Jan; 171(1-2):137-49. PubMed ID: 11165022
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of aldo-keto reductases AKR1C1-AKR1C4.
Brožič P; Turk S; Rižner TL; Gobec S
Curr Med Chem; 2011; 18(17):2554-65. PubMed ID: 21568892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
